We sat down to talk shop with Novo Nordisk Executive Vice President Ludovic Helfgott

One decade behind the EU, biosimilars are arriving in the US. What can we expect? Jeff Baldetti from Cardinal Health has a few ideas.

Driven by the success of COVID-19 vaccines, mRNA products are expanding drug developers’ pipelines.

How an initiative from EFPIA and a new public database on chemical substances could reduce animal experiments.

Overcoming supply chain woes will require digital intervention.

How bioelectronic assays helped demonstrate the value of 3D iPSC cultures in modeling human brain development.

Medicines Patent Pool has joined forces with over 30 generic manufacturers to help ensure access to anti-COVID-19 medicines for all.

What are the key decisions that need to be made for cell therapy supply chains?

The Medicine Maker’s round up of the top news stories in the pharma industry in March.

We find out how technology is enabling remote inspections in the pharma industry.